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At the height of his fame, he could walk past a monastery in
Tibet and Buddhist monks would look up from their prayer
wheels, point their bony fingers, and shout out his name. He
has always been one of my heroes, not for what he did in the
boxing ring (though that was magical, almost more ballet
than prizefighting, at least in his early years), but for what he
said and did outside of it. In the late 1960s, when, like a lot
of other young men, I was trying to prove to people, includ-
ing myself, that being against the Vietnam War didn’t neces-
sarily mean that you were a coward, he went to jail for
refusing to be drafted into what he considered an unjust war
(“No Vietcong,” he said memorably, “ever called me a
nigger.”). With that gesture, the problem was solved. No one
could ever accuse Mohammed Ali of being a coward. 
Now he is a shaking, slurred-speaking shadow of that quick-
witted, loud-mouthed, powerful, graceful young man.
Parkinson’s Disease has done what no single opponent, not
even the United States government, could do: it has taken
away the essence of the man and left us with a shadow -
externally, for the real cruelty of Parkinson’s is that its
victims are usually fine mentally. They know exactly what is
happening to them, they simply can no longer control their
bodies because the dopaminergic neurons in the substantia
nigra of their midbrain, the region that generates smooth
movement, are dying. 
Mohammed Ali’s Parkinson’s Disease was brought on by
inflammation caused by years of repeated trauma to the
brain from his chosen profession. It will kill him eventually,
as it does most sufferers unless they die of something else
first. Over a period of about twenty years, the afflicted slowly
lose all voluntary mobility, becoming prisoners inside their
bodies, until at last, unable to even swallow, they succumb to
pneumonia or some other proximate cause of death. Parkin-
son’s is an ancient disease, and it is likely that some of the
fables of people turning to stone (the Medusa’s lethal gaze in
Greek mythology; the petrification of trolls in Scandinavian
legends - virtually every country has such stories) represent
attempts by primitive people to explain something that must
have seemed an incomprehensible horror. 
The same fate awaits the actor Michael J. Fox, whose Parkin-
son’s Disease is probably the result of some genetic flaw,
given that its age of onset was so early. It also awaits Pope
John Paul II, whose Parkinson’s appeared in old age, as it
most often does. The disease affects around 1% of those over
65; their condition is referred to as idiopathic or ‘sporadic’
Parkinson’s, since no single cause, genetic or otherwise, has
been identified. (Like a lot of other ‘sporadic’ disorders,
including Type I Diabetes, Alzheimer’s Disease (the non-
familial form) and schizophrenia, Parkinson’s Disease is
probably polygenic, with multiple contributing factors that
dispose towards getting it, combined perhaps with environ-
mental factors.) That fate also awaits the close to 1 million
Americans and millions worldwide who currently suffer
from this affliction. 
And if US President George W. Bush and others in his
administration have their way, that fate is certain. Currently
there is no effective treatment for Parkinson’s Disease;
dopamine replacement is palliative only and loses its effec-
tiveness over time. Despite some new therapies that seem to
help ease the disease’s debilitating symptoms in some
patients, nothing can either replace the faulty nerve cells
that cause the disease or stop Parkinson’s from progressing.
Medical care for those afflicted with Parkinson’s, combined
with their loss of productivity, cost US$ 5.6 billion a year in
the US alone, and right now there is only one real hope for
these sufferers. That hope is embryonic stem (ES) cell
therapy, which depends on research that the Bush adminis-
tration is doing its best to strangle. 
They will tell you otherwise, but they’re not telling the truth.
In a recent speech, Laura Bush, the President’s wife, claimed
that Bush is the only president to authorize federal funding
for (ES) cell research. That is true, but no other president
ever had the opportunity before. She went on to claim thatthis authorization has led to $25 million in federal grants
last year. Also true, but misleading: $25 million is an
insignificant sum for such work, and the reason the amount
is so small is that Bush has hamstrung those trying to do the
research with untenable restrictions. In an address to the
nation in July of 2001, Bush prohibited the use of federal
funds to create new lines of ES cells or to carry out research
using lines so created. He stated that federal funds could be
used to work with any of the 78 lines of ES cells then in exis-
tence, but this was disingenuous for several reasons. First,
only about 20 of these lines were thought suitable for most
studies - as has proven to be the case. Second, none of these
lines were genetically matched to any patient, the most
important direction of research for disease treatment, and
under the Bush guidelines no patient-matched lines could be
created with government support and no federally funded
research could be done with them regardless of where they
came from. These restrictions have had two consequences:
to drive some stem cell researchers out of the US to Europe
(especially Great Britain) or Australia, where policies are
more enlightened, and to force US-based scientists to try to
find private support (from industry or foundations, such as
the Howard Hughes Medical Institutes). And the whole
notion that the Bush administration has been supportive of
ES-cell research within limits is also disingenuous, because
it is very clear that the ultimate objective is to ban it com-
pletely, regardless of the source of funds. The US House of
Representatives passed just such an administration-supported
ban last year, but the Senate defeated it. If the Republicans
hold onto their majority in the upcoming elections this
November, a ban is certain to be brought up again. 
Moreover, the Bush administration is trying to export its
policy to the rest of the world. On Monday 8 December 2003,
the United Nations General Assembly almost voted to ban all
forms of human cloning, both reproductive and therapeutic
(ES cell research is sometimes referred to, inappropriately and
foolishly in my view, as therapeutic human cloning). In the
end, it was decided to delay action to allow more deliberation.
Sometime this fall the matter will probably be reconsidered.
The United States is a prime sponsor of the resolution, along
with - here’s an example of strange bedfellows if ever there
was one - a group of fundamentalist Muslim countries. 
What is so controversial about a technology that has the
potential to help people who suffer from incurable condi-
tions such as Parkinson’s and Alzheimer’s Diseases, spinal
injuries, and Type I (juvenile onset) Diabetes, all of which
are characterized by the loss of particular types of cells and
therefore can only really be cured by the generation of
replacement cells? The crux of the matter lies in the way in
which new lines of ES cells are created, a process most prop-
erly called somatic cell nuclear transfer (SCNT). In this pro-
cedure, the nucleus of an unfertilized egg is removed and
replaced with, for example, the nucleus of a patient’s own
cells (including skin, heart and nerve cells), which are called
somatic cells. When the resulting egg has divided into a
small number of stem cells, which have not yet differentiated
but are capable of doing so, these cells can be harvested for
research or for disease treatment. The goal of SCNT is to
develop stem cells that will not be rejected or destroyed by
the patient’s immune system and that can differentiate into
any desired cells, such as neurons of the substantia nigra, or
pancreatic islet cells. Somatic cell nuclear transfer could thus,
in principle, allow patients to be cured using their own DNA.
To call it a form of human cloning demonizes it by associating
it with cloning for reproductive purposes, and ignores the fact
that SCNT produces only stem cells, never babies. No sperm
is used in SCNT and the cells are not transplanted into any
womb. But religious conservatives object to the procedure
because it involves the formation and subsequent destruction
of a very early stage embryo (or, at least, destruction in the
case of harvesting ES cells from existing embryos obtained
from fertility clinics. Such ES cells would not be genetically
matched to any person, but are still very useful; nearly all
existing lines of ES cells have been obtained this way. Geneti-
cally matched ES cell lines are necessary to treat or model
diseases, but their creation is a new development.) 
I have a great deal of respect for those who are against this
research for sincerely held, consistent moral beliefs, although I
disagree with them. But I’m not sure the Bush administration
fits that description. There is much in the administration’s
words and actions to suggest that this issue is actually a stalk-
ing-horse for something else: an attempt to ban all forms of
pregnancy termination (abortion), even in cases of rape and
incest. And I have a problem with the inconsistency of claiming
to be pro-life by favoring embryos whose status as ‘living’ is
open to debate while condemning people who are unequivo-
cally alive to certain death. That stance also ignores the suffer-
ing of their friends and families (to get a sense of what they go
through, I recommend ‘Saving Milly’, by Morton Kondracke,
published by Balantine Books: New York; 2001; if after reading
it you can still argue that a collection of undifferentiated cells
should take precedence over human beings like those in this
book, then nothing I can say is likely to change your mind). 
To be fair, scientists haven’t helped themselves much in this
debate. Like gene therapy and the war on cancer and the
human genome project, stem-cell research has been oversold
by some, especially for Alzheimer’s Disease where its applica-
tions are tenuous and very far away. Replacement of cogni-
tive neurons, with their complex web of synapses, is likely to
be extremely difficult. Nor will it replace the lost memories
that are a large part of the burden of the disease - for we are
our memories, they create the shape of our life. But for Type
II diabetes, spinal cord injuries, Parkinson’s Disease and
other motor neuron diseases, it really does represent, in my
opinion, the most promising line of research at the moment. 
Ron Reagan, the son of the late President Ronald Reagan,
understands that well. At the Democratic National Convention
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quence about the importance of embryonic stem-cell
research. The whole speech is worth reading (you can find a
transcript online at [http://politicalgateway.com/news/
read.html?id=535]); here are some parts of it: “There are
those who would stand in the way of this remarkable future,
who would deny the federal funding so crucial to basic
research. They argue that interfering with the development
of even the earliest stage embryo, even one that will never be
implanted in a womb and will never develop into an actual
fetus, is tantamount to murder. A few of these folks, needless
to say, are just grinding a political axe and they should be
ashamed of themselves. But many are well-meaning and
sincere. Their belief is just that, an article of faith, and they
are entitled to it. But it does not follow that the theology of a
few should be allowed to forestall the health and well-being
of the many. And how can we affirm life if we abandon those
whose own lives are so desperately at risk? It is a hallmark of
human intelligence that we are able to make distinctions.
Yes, these cells could theoretically have the potential, under
very different circumstances, to develop into human beings -
that potential is where their magic lies. But they are not, in
and of themselves, human beings. They have no fingers and
toes, no brain or spinal cord. They have no thoughts, no
fears. They feel no pain. Surely we can distinguish between
these undifferentiated cells multiplying in a tissue culture
and a living, breathing person - a parent, a spouse, a child...
“What might we tell… the millions of others who suffer? That
when given an opportunity to help, we turned away? That
facing political opposition, we lost our nerve? That even
though we knew better, we did nothing? And, should we fail,
how will we feel if, a few years from now, a more enlightened
generation should fulfill the promise of embryonic stem cell
therapy? Imagine what they would say of us who lacked the
will... The tide of history is with us. Like all generations who
have come before ours, we are motivated by a thirst for
knowledge and compelled to see others in need as fellow
angels on an often difficult path, deserving of our compas-
sion… We have a chance to take a giant stride forward for the
good of all humanity. We can choose between the future and
the past, between reason and ignorance, between true com-
passion and mere ideology. This is our moment, and we
must not falter.”
I hope our leaders will find the wisdom to heed his call. Even if
they do, any cure for Parkinson’s Disease will certainly come
too late to save Mohammed Ali. But if his suffering moves
even a few to the compassion needed to support the best hope
for those like him, then his torment will have meant some-
thing. The death of a hero should have some meaning. 
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